The New England Journal of Medicine reported a significant advance in the fight against prostate cancer in July 2013—the availability and efficacy of a radiopharmaceutical agent that targets prostate cancer with bone metastases. The treatment is a serious of six injections given monthly.
Radium-223 (Xofigo) is an alpha emitter with calcium mimetic properties that localizes in the bones. Use of this agent was associated with a 30% reduction in the risk of death compared with placebo in patients with castration resistant prostate cancer. Docetaxel chemotherapy can be used along with Xofigo, and the agent had a very favorable toxicity profile, with no increased hematologic or nonhematologic toxicity compared with placebo. Patients receiving Xofigo also had an improved quality of life.
We will be offering Xofigo as treatment for castration resistant prostate cancer with bone metastases. Please contact us (708-448-9393) with any questions.